Rationale, evidence base, and implications for rheumatology patients
A number of rheumatology drugs are undergoing investigation for the treatment or prevention of COVID-19.
In this series of podcasts we talk to the experts about the rationale behind rheumatology drug repurposing, data on the different agents, and the potential impact on rheumatology practice.
In the introductory podcast for our series on repurposing rheumatology drugs for COVID-19, Jinoos Yazdany discusses the rationale behind investigating these agents and explores the role of rheumatologists in ensuring they are studied as safely and efficiently as possible.
Views from professional organizations
Representatives from EULAR, the COVID-19 Global Rheumatology Alliance, and the Lupus Foundation of American identify the potential pitfalls to avoid when it comes to the repurposing of rheumatology drugs for COVID-19.
EULAR President
[Rheumatologists] can bring an extensive knowledge base to ensure that various immune modifiers that act across the range of immune effector function, can be trialled as safely and efficiently as possible.
Chair of the COVID–19 Global Rheumatology Alliance
While there is much suggestive observational data about a number of agents, definitive data can only come from randomized clinical trials so our efforts have to focus on them.
Vice President, Advocacy & Government Relations, Lupus Foundation of America
People with lupus rely greatly on hydroxychloroquine to treat the disease, including reducing disease activity and preventing flares and reducing organ damage.
